

---

Specimen Collected: 29-Oct-25 13:42

---

Chimerism, Recipient, Pre-Transplant | Received: 29-Oct-25 13:42 Report/Verified: 10-Nov-25 15:05

Procedure	Result	Units	Reference Interval
Chimerism Recipient Pre, Specimen Whole Blood			
Chimerism Recipient Pre, InformativeLoci	9		
Chimerism Recipient Pre, Interpretation	Informative <sup>f1 i1</sup>		

**Result Footnote**

f1: Chimerism Recipient Pre, Interpretation

This result has been reviewed and approved by [REDACTED]

**Test Information**

i1: Chimerism Recipient Pre, Interpretation

BACKGROUND INFORMATION: Chimerism, Recipient Pretransplant

INDICATION: Monitoring for bone marrow transplant patients; correlation with clinical status and consideration of the interval between bone marrow transplantation and testing is necessary for proper interpretation of results.

METHODOLOGY: PCR followed by capillary electrophoresis. Specimens are analyzed using 15 autosomal markers (D8S1179, D21S11, D7S820, CSF1PO, D3S1358, TH01, D13S317, D16S539, D2S1338, D19S433, vWa, TPOX, D18S51, D5S818 and FGA) and one gender marker (amelogenin).

LIMITATIONS: Diagnostic errors can occur due to rare sequence variations.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

---

\*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

---

**Unless otherwise indicated, testing performed at:****ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

**ARUP Accession:** 25-302-900261**Report Request ID:** 20897749**Printed:** 10-Nov-25 15:38

Page 1 of 1